Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $44 billion in 2021, a nearly 16% increase from the previous year, according to the Health Resources & Service Administration, which oversees the program.
The data mark a steady rise in sales under the 340B Drug Discount Program, which requires drugmakers to offer discounts that are typically estimated to be 25% to 50% — but could be higher — on all outpatient drugs to hospitals and clinics that primarily serve lower-income patients. There are roughly 12,400 entities participating in the program, a number that has grown substantially.
Create a display name to comment
This name will appear with your comment